Advertisement
News
Subscribe to MDT Magazine News

Studies: Pneumonia is misdiagnosed on patient readmissions

October 22, 2010 9:32 am | by EurekAlert | Comments

(Henry Ford Health System) Patients were misdiagnosed with pneumonia at an alarming rate when they were readmitted to the hospital shortly after a previous hospitalization for the same illness, according to two Henry Ford Hospital companion studies.

TOPICS:

Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results

October 22, 2010 9:32 am | by Bio-Medicine.Org | Comments

BALTIMORE, Oct. 22 /- Pharmaceutical company Pharmaxis (ASX: PXS) today announced significant results of pooled data from its two large scale six month Phase III trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis. The combined results have been presented for the first...

TOPICS:

Boston Scientific Announces CE Mark Approval for Expanded Indication of WallFlex® Biliary RX Stent

October 22, 2010 8:31 am | by Bio-Medicine.Org | Comments

NATICK, Mass., Oct. 22 /- Boston Scientific Corporation (NYSE: BSX ) today announced that its WallFlex® Biliary RX Fully Covered Stent has received CE Mark approval for the treatment of benign biliary strictures.   "The WallFlex Biliary RX Fully Covered Stent has proved...

TOPICS:
Advertisement

GE Healthcare to Acquire Cancer Diagnostic Company Clarient Inc.

October 22, 2010 8:31 am | by Bio-Medicine.Org | Comments

CHALFONT ST GILES, UK and ALISO VIEJO, Calif., Oct. 22 /- GE Healthcare, a unit of General Electric Company (NYSE: GE ), and Clarient, Inc. (Nasdaq: CLRT ) announced today that they have entered into a definitive agreement for GE Healthcare to acquire Clarient, a leading player in the...

TOPICS:

Summary Box: GE to buy diagnostics firm Clarient

October 22, 2010 7:45 am | by The Associated Press | Comments

THE DEAL: General Electric Co. said its healthcare unit will buy diagnostics company Clarient Inc. to speed its expansion into cancer diagnostic and therapy selection tools.THE PARTICULARS: GE will start a cash tender offer of $5 per share for Clarient common stock and $20 for each preferred share....

Scorpion has welcome sting for heart bypass patients

October 22, 2010 7:34 am | by EurekAlert | Comments

(University of Leeds) A toxin found in the venom of the Central American bark scorpion (Centruroides margaritatus) could hold the key to reducing heart bypass failures, according to research from the University of Leeds.

TOPICS:

CEO Termeer: Genzyme worth even more – $89 per share

October 22, 2010 7:33 am | by Mass High Tech: The Journal of New England Technology | Comments

Genzyme Corp. CEO Henri Termeer said the company’s profits will more than double next year, and that proves the company has been significantly undervalued by the acquisition offer of $69 per share from French drug maker Sanofi-aventis.

INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine

October 22, 2010 7:32 am | by Bio-Medicine.Org | Comments

DENVER and BEVERLY, Mass., Oct. 22 /- INVO Bioscience, Inc. (OTC Bulltin Board: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, today announced that Dr. Elkin Lucena of the Columbian Fertility and Sterility Center (CECOFLES LTDA) will...

TOPICS:
Advertisement

Social interaction can identify mental pathology

October 22, 2010 7:32 am | by Baylor College of Medicine | Comments

If your doctor thinks your blood pressure is too high, she can measure it with an instrument. If she thinks you are anemic, she can order a lab test. Psychiatrists seeking to identify mental disorders must depend on less precise measures – observations of behaviors and various...

TOPICS:

Children's Hospital granted $3M to study rare blood disease

October 22, 2010 7:32 am | by Mass High Tech: The Journal of New England Technology | Comments

Children’s Hospital Boston has received a $3.9 million grant from the National Institutes of Health to work on a treatment on a fatal genetic blood disease called Fanconi anemia.

TOPICS:

Thoratec Schedules Third Quarter Conference Call, Webcast

October 22, 2010 7:32 am | by Bio-Medicine.Org | Comments

PLEASANTON, Calif., Oct. 22 /- Thoratec Corporation (Nasdaq: THOR ), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the third quarter and first nine months...

TOPICS:

GE to buy diagnostics company Clarient

October 22, 2010 6:45 am | by The Associated Press | Comments

General Electric Co. said Friday its healthcare unit will buy diagnostics company Clarient Inc. in a deal aimed at speeding its expansion into cancer diagnostic and therapy selection tools.GE Healthcare officials say the deal will help them build a $1 billion-plus business developing integrated...

St. Jude Medical to buy back up to $300M in shares

October 22, 2010 6:45 am | by The Associated Press | Comments

St. Jude Medical Inc., a medical device maker, said Friday it will repurchase up to $300 million in stock.The program is in addition to the $600 million share repurchase program already announced.Shares acquired during the program will be used for general corporate purposes. The company had...

Teaching kids to work through trauma

October 22, 2010 6:34 am | by EurekAlert | Comments

(American Friends of Tel Aviv University) A child who grows up in the midst of political conflict, such as war or terrorism, can exhibit severe emotional scars. But certain qualities, which psychologists call "resilience factors," can help overcome this adversity. Prof. Michelle...

TOPICS:

Boston Scientific Announces CE Mark Approval for Expanded Indication of WallFlex® Biliary RX Stent

October 22, 2010 4:32 am | by Boston Scientific | Comments

Company's fully covered metal stent now approved for use in treating benign biliary strictures

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading